Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Arct-154 symbols : TAK save search
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: -1.16%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: 6.93%
H: 1.13%
C: -8.47%
arct-154 trial results
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.17%
H: 0.68%
C: 0.27%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: -20.04%
H: 28.04%
C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
Published: 2022-01-25 (Crawled : 13:30) - biospace.com/
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.76%
H: 2.02%
C: 1.04%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.37%
H: 3.73%
C: 3.25%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: 0.24%
H: 4.13%
C: 1.44%
arct-154 trial therapeutics response sars-cov-2 report pons antibody
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
Published: 2022-01-24 (Crawled : 14:00) - biospace.com/
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.18%
H: 0.34%
C: -0.69%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -1.19%
H: 0.1%
C: -0.63%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: -2.85%
H: 3.12%
C: 2.09%
arct-154 trial therapeutics response sars-cov-2 pons antibody
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
Published: 2021-12-16 (Crawled : 14:00) - biospace.com/
TAK | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 1.18%
H: 0.0%
C: 0.0%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
ARCT 4 | $26.31 -4.81% -5.06% 610K
|
Health Technology
|
| O: 10.59%
H: 17.58%
C: 13.16%
arct-154 als trials trial therapeutics clinical trials
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | $1.02 155.0% 60.78% 120M
|
Finance
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 900K
|
OST | $0.499 21.38% 45.26% 1.9M
|
ZCMD | $2.44 78.1% 43.85% 330K
|
Commercial Services
XPON | $3.1 60.62% 37.74% 16M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.